Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 4, pp 921–927 | Cite as

Traditional Chinese medicine and drug-induced anaphylaxis: data from the Beijing pharmacovigilance database

  • Xiaotong Li
  • Sydney Thai
  • Wenchao Lu
  • Shusen Sun
  • Huilin Tang
  • Suodi Zhai
  • Tiansheng WangEmail author
Research Article

Abstract

Background Traditional Chinese medicine (TCM) is one of the major triggers for drug-induced anaphylaxis (DIA). Objective We aimed to use the Beijing pharmacovigilance database (BPD) to analyze TCM-induced DIAs in Beijing, China. Setting Drug allergy case reports from the BPD provided by the Beijing Center for Adverse Drug Reaction Monitoring. Method Drug allergy cases from January 2004 to December 2014 were adjudicated. DIA triggered by TCMs were analyzed and compared with those triggered by non-TCM drugs by calculating the reported risk ratio (RRR). We also calculated the RRRs based on severe DIA and death outcomes. Main outcome measure TCMs implicated in DIAs were identified and compared with non-TCM drugs. Results TCMs accounted for 1651 (18.2%) of the total 9074 allergic cases, in which 84.4% (1393/1651) were triggered by injections. Of the TCM allergic cases, 8.5% (141) were DIAs and 7.3% (120) were severe DIAs, and three patients died from injections. The RRR between TCMs and non-TCM-induced DIAs was 0.63. When anaphylactic cases were compared between TCMs to the top four non-TCM drug triggers, RRRs were 0.73 (95% CI 0.61–0.87) for antibiotics, 0.36 (95% CI 0.29–0.44) for radiocontrast agents, 0.55 (95% CI 0.43–0.68) for chemotherapeutics, and 0.29 (95% CI 0.23–0.37) for biologics. Compared to TCM oral or topic formulations, TCM injections had higher RRRs in each of the above comparisons. Conclusion TCM was associated with a decreased risk of DIA compared to non-TCM drugs in drug allergy cases, and the risk was higher for TCM injections.

Keywords

China Drug-induced anaphylaxis Pharmacovigilance Traditional Chinese medicines 

Notes

Acknowledgements

The authors would like to thank the Beijing pharmacovigilance database for providing data.

Funding

This research received no funding from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Supplementary material

11096_2018_699_MOESM1_ESM.docx (44 kb)
Supplementary material 1 (DOCX 46 kb)

References

  1. 1.
    Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy. 2014;69(4):420–37.CrossRefPubMedGoogle Scholar
  2. 2.
    American Academy of Allergy, Asthma & Immunology. MEDICATIONS AND DRUG ALLERGIC REACTIONS. https://www.aaaai.org/conditions-and-treatments/allergies/drug-allergy. Accessed 27 May 2018.
  3. 3.
    Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026–45.CrossRefPubMedGoogle Scholar
  4. 4.
    Simons FE, Ebisawa M, Sanchez-Borges M, Thong BY, Worm M, Tanno LK, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):1–16.CrossRefGoogle Scholar
  5. 5.
    Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States 1999–2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134(6):1318.e7–1328.e7.CrossRefGoogle Scholar
  6. 6.
    Ribeiro-Vaz I, Marques J, Demoly P, Polónia J, Gomes ER. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority. Eur J Clin Pharmacol. 2013;69(3):673–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhao Y, Sun S, Li X, Ma X, Tang H, Sun L, et al. Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing pharmacovigilance database. Int J Clin Pharm. 2017;8:1–10.Google Scholar
  8. 8.
    Jiang N, Yin J, Wen L, Li H. Characteristics of anaphylaxis in 907 Chinese patients referred to a tertiary allergy center: a retrospective study of 1,952 episodes. Allergy Asthma Immunol Res. 2016;8(4):353.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wang T, Ma X, Xing Y, Sun S, Zhang H, Stürmer T, et al. Use of epinephrine in patients with drug-induced anaphylaxis: an analysis of the Beijing pharmacovigilance database. Int Arch Allergy Immunol. 2017;173(1):51.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Xing Y, Zhang H, Sun S, Ma X, Pleasants RA, Tang H, et al. Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data. Eur J Pediatr. 2018;177(1):145–54.CrossRefPubMedGoogle Scholar
  11. 11.
    Brown AF, Mckinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol. 2001;108(5):861–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Sweetman SC. Martindale 37: the complete drug reference. London: Pharmaceutical Press; 2011. ISBN 9780853699330.Google Scholar
  13. 13.
    World Health Organization. WHO model formulary 2008. ISBN 9789241547659. http://apps.who.int/medicinedocs/en/m/abstract/Js16879e/. Accessed 7 May 2018.
  14. 14.
    Chinese Pharmacopoeia Commission. Chinese pharmacopoeia, vol. I. Beijing: China Medical Science Press; 2015.Google Scholar
  15. 15.
    Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157–66.CrossRefPubMedGoogle Scholar
  16. 16.
    Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang SL, Wang Y, Sun J, Xu HM. Analysis of 79 cases of irritability shock caused by traditional Chinese medicine preparations. Chin J Pharmacoepidemiol. 2008;17(4):235–7 (Chinese).Google Scholar
  18. 18.
    Dingxiangyuan Drug Information. Prescribing information of Qingkailing injection. http://drugs.dxy.cn/drug/89365.htm. Accessed 27 May 2018 (Chinese).
  19. 19.
    Dingxiangyuan Drug Information. Prescribing information of Shuanghuanglian injection. http://drugs.dxy.cn/drug/89619.htm. Accessed 27 May 2018 (Chinese).
  20. 20.
    Dingxiangyuan Drug Information. Prescribing information of Houttuynia cordata injection. http://drugs.dxy.cn/drug/123449.htm. Accessed 27 May 2018 (Chinese).
  21. 21.
    Dingxiangyuan Drug Information. Prescribing information of Ciwujia injection. http://drugs.dxy.cn/drug/89603.htm. Accessed 27 May 2018 (Chinese).
  22. 22.
    Dingxiangyuan Drug Information. Prescribing information of Shuxuening injection. http://drugs.dxy.cn/drug/88059.htm. Accessed 27 May 2018 (Chinese).
  23. 23.
    Dingxiangyuan Drug Information. Prescribing information of Salvia injection. http://drugs.dxy.cn/drug/89164.htm. Accessed 27 May 2018 (Chinese).
  24. 24.
    Ochoa PS, Vega JA. Concepts in sterile preparations and aseptic technique. Burlington: Jones & Bartlett Learning; 2014.Google Scholar
  25. 25.
    Feng Y. Literature analysis of 187 allergic reactions associated with traditional Chinese medicines. Adverse Drug React J. 2002;4(2):81 (Chinese).Google Scholar
  26. 26.
    Cao HS, He PB, Yang LZ. Analysis of 288 anaphylaxis cases induced by herb injections. Chin J Pharmacoepidemiol. 2006;15(1):26–7 (Chinese).Google Scholar
  27. 27.
    Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, et al. Pharmacovigilance practice and risk control of Traditional Chinese medicine drugs in China: current status and future perspective. J Ethnopharmacol. 2012;140(3):519.CrossRefPubMedGoogle Scholar
  28. 28.
    Ng A, Poon SL, Huang MN, Lim JQ, Boot A, Yu W, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med. 2017;9(412):eaan6446.CrossRefPubMedGoogle Scholar
  29. 29.
    Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA. 2012;109(21):8241–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of PharmacyPeking University Third HospitalBeijingChina
  2. 2.Institute for Drug Evaluation, Peking University Health Science CenterBeijingChina
  3. 3.Department of Pharmacy Administration and Clinical PharmacyPeking University Health Science CenterBeijingChina
  4. 4.Department of Epidemiology, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel HillUSA
  5. 5.College of Pharmacy and Health SciencesWestern New England UniversitySpringfieldUSA
  6. 6.Department of Epidemiology, Richard M. Fairbanks School of Public HealthIndiana UniversityIndianapolisUSA

Personalised recommendations